Avalere Health President, Dan Mendelson, points to value-based contracting as the better pricing strategy and encourages the pharma industry to focus their energy on those type of contracts. However, Mendelson also believes that rebates aren’t going anywhere anytime soon and will continue being the status quo. Subscription Required. (Source: Cathy Kelly, The Pink Sheet, 1/16/17)
You are here: / / Would Pharma Benefit More From Value-Based Contracts?